期刊
EXPERT REVIEW OF RESPIRATORY MEDICINE
卷 15, 期 11, 页码 1377-1386出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17476348.2021.1985763
关键词
asthma; asthma epidemiology; asthma genetics; COVID-19; asthma treatment
Asthma may pose an increased risk for severe COVID-19, particularly for those with severe disease or non-allergic phenotypes. COVID-19 does not seem to trigger asthma exacerbations, and asthma therapeutics should be continued for patients exposed to COVID-19.
Introduction: Asthma is one of the most common chronic diseases worldwide. As a disease of the respiratory tract, the site of entry for the SARS-CoV-2 virus, there may be an important interplay between asthma and COVID-19 disease. Areas covered: We report asthma prevalence among hospitalized cohorts with COVID-19. Those with non-allergic and severe asthma may be at increased risk of a worsened clinical outcome from COVID-19 infection. We explore the epidemiology of asthma as a risk factor for the severity of COVID-19 infection. We then consider the role COVID-19 may play in leading to exacerbations of asthma. The impact of asthma endotype on outcome is discussed. Lastly, we address the safety of common asthma therapeutics. A literature search was performed with relevant terms for each of the sections of the review using PubMed, Google Scholar, and Medline. Expert opinion: Asthma diagnosis may be a risk factor for severe COVID-19 especially for those with severe disease or nonallergic phenotypes. COVID-19 does not appear to provoke asthma exacerbations and asthma therapeutics should be continued for patients with exposure to COVID-19. Clearly much regarding this topic remains unknown and we identify some key questions that may be of interest for future researchers. [GRAPHICS] .
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据